Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial
Abstract
AIMS: An analysis was designed to determine whether chronic heart failure patients at high cardiovascular risk benefited to the same extent from high-dose lisinopril as the whole ATLAS population. METHODS AND RESULTS: A retrospective analysis was performed on high-risk heart failure patients in the Assessment of Treatment with Lisinopril And Survival (ATLAS) trial (total number of patients 3164) comparing highdose (32.5-35 mg. day(-1)) vs low-dose (2.5-5 mg. day(-1)) lisinopril for a median of 46 months. These high-risk patients included those with hypotension, hyponatraemia, compromised renal function, the elderly and patients with diabetes mellitus at baseline. In the whole study population, high-dose lisinopril led to a trend in risk reduction of all-cause mortality (primary end-point P=0.128) and a significant risk reduction in all-cause mortality plus hospitalization (principal secondary end-point P=0.002). Subgroup analyses were performed for these end-points. There were no consistent interactions between age, baseline sodium, creatinine or potassium values, and treatment effect. Diabetics showed a beneficial response to high-dose therapy that was at least as good as that in non-diabetics. The underlying higher morbidity/mortality rates in diabetics mean that high-dose lisinopril has potential for a larger absolute clinical impact in these patients. CONCLUSION: Long-term high-dose lisinopril was as effective and well-tolerated in high-risk patients, including those with diabetes mellitus, as for the ATLAS study population as a whole.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The absolute benefit of high-dose lisinopril was larger in patients with T2DM because they were at greater risk.
“However, because patients with T2DM were at greater risk, the absolute benefit of high-dose lisinopril was larger in patients with T2DM.144”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [144]
The greater relative benefit for the composite primary endpoint (all-cause mortality or HF hospitalization) of high-dose lisinopril was similar in patients with and without T2DM.
“The greater relative benefit for the composite primary endpoint (all-cause mortality or HF hospitalization) of high-dose lisinopril was similar in patients with and without T2DM.”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [144]
The occurrence of adverse effects with high-dose lisinopril was similar in those with and without T2DM with respect to hypotension/dizziness, renal dysfunction/hyperkalaemia and cough.
“The occurrence of adverse effects with high-dose lisinopril was similar in those with and without T2DM with respect to hypotension/dizziness (35% vs. 32%), renal dysfunction/hyperkalaemia (29% vs. 22%) and cough (12% vs. 10%).144”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [144]
Cites
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029 · see citing works
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400 · see citing works
Murray, G. D., Moss, A. J., Murray, G., Poole-Wilson, P., Ml, S., Ball, S., Bender, N., Cleland, J. G. F., Dl, C., Pj, C., et al. (1993) · PubMed · Cited by 2,126 · see citing works
Julian, D. G., Moss, A. J., Murray, G. D., Poole-Wilson, P. A., Simoons, M. L., Ball, S., Bender, N., Cleland, J. G. F., Dl, C., Pj, C., et al. (1993) · The Lancet · Cited by 1,860 · see citing works
Packer, M., Poole-Wilson, P. A., Armstrong, P. W., Cleland, J. G. F., Horowitz, J. D., Massie, B. M., Rydén, L., Thygesen, K., & Uretsky, B. F. (1999) · Circulation · doi:10.1161/01.cir.100.23.2312 · Cited by 1,244 · see citing works
Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes
Chaturvedi, N., Sjolie, A.-K., Stephenson, J., Abrahamian, H., Keipes, M., Castellarin, A., Rogulja-Pepeonik, Ž., & Fuller, J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)06209-0 · Cited by 738 · see citing works
Chaturvedi, N. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10244-0 · Cited by 526 · see citing works
Danet, S., Richard, F., Montaye, M., Beauchant, S., Lemaire, B., Graux, C., Cottel, D., Marécaux, N., & Amouyel, P. (1999) · Circulation · doi:10.1161/01.cir.100.1.e1 · Cited by 503 · see citing works
Chrome congestive heart failure
MADSEN, B. K., Hansen, J., Stokholm, K. H., Brøns, J., Husum, D., & MORTENSEN, L. S. (1994) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a060495 · Cited by 210 · see citing works
Amato, L., Paolisso, G., Cacciatore, F., Ferrara, N., Ferrara, P., Canonico, S., Varricchio, M., & Rengo, F. (1997) · PubMed · Cited by 193 · see citing works
Saxon, L. A., Stevenson, W. G., Middlekauff, H. R., Fonarow, G. C., Woo, M. A., Moser, D. K., & Stevenson, L. W. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90220-7 · Cited by 180 · see citing works
Packer, M., Lee, W. H., & Kessler, P. D. (1986) · Circulation · doi:10.1161/01.cir.74.4.766 · Cited by 101 · see citing works
Drug-Induced Orthostatic Hypotension in the Elderly
Verhaeverbeke, H., & Mets, T. F. (1997) · Drug Safety · doi:10.2165/00002018-199717020-00003 · Cited by 95 · see citing works
Packer, M. (1996) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00301-4 · Cited by 82 · see citing works
Clinical Pharmacokinetics of Angiotensin Converting Enzyme (ACE) Inhibitors in Renal Failure
Hoyer, J. D., Schulte, K.-L., & Lenz, T. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324030-00005 · Cited by 75 · see citing works
Oster, J. R. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.1992.00400160022006 · Cited by 58 · see citing works
ACE inhibitors for heart failure: a question of dose
Cleland, J. G. F., & Poole-Wilson, P. A. (1994) · Heart · doi:10.1136/hrt.72.3_suppl.s106 · Cited by 45 · see citing works
Massie, B. M., Cleland, J. G. F., Armstrong, P. W., Packer, M., Poole-Wilson, P. A., & Lars, R. (1998) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(98)90502-4 · Cited by 40 · see citing works
Cleland, J. G. F., Armstrong, P. W., Horowitz, J. D., Massie, B. M., Packer, M., Poole-Wilson, P. A., & Rydén, L. (1999) · European Journal of Heart Failure · doi:10.1016/s1388-9842(98)00002-6 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763 · see citing works
Authors Task Force Members, Rydén, L., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,958 · see citing works
Jia, G., Hill, M. A., & Sowers, J. R. (2018) · Circulation Research · doi:10.1161/circresaha.117.311586 · Cited by 1,838 · see citing works
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary
Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M., Cosentino, F., Jönsson, B., Laakso, M., Malmberg, K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl260 · Cited by 1,638 · see citing works
Seferović, P. M., Petrie, M. C., Filippatos, G. S., Anker, S. D., Rosano, G., Bauersachs, J., Paulus, W. J., Komajda, M., Cosentino, F., de Boer, R. A., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1170 · Cited by 708 · see citing works
Rydén, L., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H., Huikuri, H., et al. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.10.013 · Cited by 609 · see citing works
Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019
Précoma, D. B., de Oliveira, G. M. M., Simão, A. F. L., Dutra, Ó. P., Coelho-Filho, O. R., Izar, M. C. D. O., Póvoa, R., Giuliano, I. D. C. B., Filho, A. C. D. A., Machado, C. A., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190204 · Cited by 469 · see citing works
Diabetic cardiomyopathy: pathophysiology and clinical features
Miki, T., Yuda, S., Kouzu, H., & Miura, T. (2013) · Heart Failure Reviews · doi:10.1007/s10741-012-9313-3 · Cited by 460 · see citing works
Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure
Dei Cas, A., Khan, S. S., Butler, J., Mentz, R. J., Bonow, R. O., Avogaro, A., Tschoepe, D., Doehner, W., Greene, S. J., Senni, M., et al. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2014.08.004 · Cited by 401 · see citing works
Diabetic cardiomyopathy: mechanisms, diagnosis and treatment
Hayat, S. A., Patel, B., Khattar, R. S., & Malik, R. A. (2004) · Clinical Science · doi:10.1042/cs20040057 · Cited by 350 · see citing works
Diabetes in heart failure: prevalence and impact on outcome in the population
From, A. M., Leibson, C. L., Bursi, F., Redfield, M. M., Weston, S. A., Jacobsen, S. J., Rodeheffer, R. J., & Roger, V. L. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.05.024 · Cited by 295 · see citing works
Mitochondrial ROS Formation in the Pathogenesis of Diabetic Cardiomyopathy
Kaludercic, N., & Lisa, F. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00012 · Cited by 264 · see citing works
pre-diabetes Task Force on diabetes (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114525548 · Cited by 236 · see citing works
Diabetes, left ventricular systolic dysfunction, and chronic heart failure
MacDonald, M. R., Petrie, M. C., Hawkins, N. M., Petrie, J. R., Fisher, M., McKelvie, R., Aguilar, D., Krum, H., & McMurray, J. J. V. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn156 · Cited by 227 · see citing works
Influence of diabetes mellitus on heart failure risk and outcome
Bauters, C., Lamblin, N., Fadden, E. P. M., BELLE, E. V., Millaire, A., & de Groote, P. (2003) · Cardiovascular Diabetology · doi:10.1186/1475-2840-2-1 · Cited by 213 · see citing works
Voulgari, Tentolouris, N., & Papadogiannis, D. E. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s11681 · Cited by 208 · see citing works
Haas, S. J., Vos, T., Gilbert, R. E., & Krum, H. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00403-4 · Cited by 194 · see citing works
Impact of diabetes mellitus on long-term survival in patients with congestive heart failure
de Groote, P. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.01.010 · Cited by 192 · see citing works
Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management
Pappachan, J. M., Varughese, G. I., Sriraman, R., & Arunagirinathan, G. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.177 · Cited by 190 · see citing works
Diabetic cardiomyopathy: where we are and where we are going
Lee, W. S., & Kim, J. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.208 · Cited by 167 · see citing works
Vaur, L., Gueret, P., Lievre, M., Chabaud, S., Passa, P., & For the DIABHYCAR Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.3.855 · Cited by 163 · see citing works
Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction
Frazier‐Mills, C. G., Alexander, K. P., Newby, L. K., Anderson, S., Iverson, E. R., Packer, M., Cohn, J. N., Goldstein, S., & Douglas, P. S. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.11.041 · Cited by 146 · see citing works
Mode of death in heart failure: findings from the ATLAS trial
Poole-Wilson, P. A., Uretsky, B. F., Thygesen, K., Cleland, J. G. F., Massie, B. M., & Rydén, L. (2002) · Heart · doi:10.1136/heart.89.1.42 · Cited by 145 · see citing works
Dauriz, M., Mantovani, A., Bonapace, S., Verlato, G., Zoppini, G., Bonora, E., & Targher, G. (2017) · Diabetes Care · doi:10.2337/dc17-0697 · Cited by 123 · see citing works
Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
Wang, L., Cai, Y., Jian, L., Cheung, C. W., Zhang, L., & Xia, Z. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01188-0 · Cited by 114 · see citing works
Frequent Non-Cardiac Comorbidities in Patients with Chronic Heart Failure
Dahlström, U. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.01.008 · Cited by 113 · see citing works
Mascarenhas, J., Lourenço, P., Lopes, R., Azevedo, A., & Bettencourt, P. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.10.040 · Cited by 109 · see citing works
The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma
Rothhammer-Hampl, T., Hahne, J. C., Florin, A., Poser, I., Soncin, F., Wernert, N., & Bosserhoff, A. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3337-8 · Cited by 108 · see citing works
Packer, M. (2017) · Diabetes Care · doi:10.2337/dci17-0052 · Cited by 106 · see citing works
Arnold, J. M. O., Howlett, J. G., Ducharme, A., Ezekowitz, J. A., Gardner, M. J., Giannetti, N., Haddad, H. A., Heckman, G. A., Isaac, D., Jong, P., et al. (2008) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(08)70545-2 · Cited by 103 · see citing works
Gilbert, R. E., Krum, H., Wilkinson‐Berka, J. L., & Kelly, D. J. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00979.x · Cited by 102 · see citing works
Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date
Athithan, L., Gulsin, G. S., McCann, G. P., & Levelt, E. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i10.490 · Cited by 93 · see citing works
Metabolic and Molecular Imaging of the Diabetic Cardiomyopathy
Peterson, L. R., & Gropler, R. J. (2020) · Circulation Research · doi:10.1161/circresaha.120.315899 · Cited by 93 · see citing works
Heart Failure and Diabetes Mellitus: Epidemiology and Management of an Alarming Association
Solal, A. C., Beauvais, F., & Logeart, D. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.04.001 · Cited by 93 · see citing works
Concomitant Diabetes Mellitus and Heart Failure
Dei, A., Fonarow, G. C., Gheorghiade, M., & Butler, J. (2014) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2014.09.002 · Cited by 92 · see citing works
Diabetic cardiomyopathy: from pathophysiology to treatment.
Trachanas, K., Sideris, S. K., Aggeli, C., Poulidakis, E., Gatzoulis, K. A., Tousoulis, D. M., & Kallikazaros, I. E. (2014) · PubMed · Cited by 86 · see citing works
Kasznicki, J., & Drzewoski, J. (2014) · Archives of Medical Science · doi:10.5114/aoms.2014.43748 · Cited by 83 · see citing works
Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes
Brooks, B. A., Franjic, B., Ban, C. R., Swaraj, K., Yue, D. K., Celermajer, D. S., & Twigg, S. M. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00803.x · Cited by 77 · see citing works
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure
Kim, M., Lee, J., Kim, E. J., Park, D.-G., Park, S., Park, J. J., Shin, M., Yoo, B., Youn, J., Lee, S. E., et al. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0009 · Cited by 76 · see citing works
A review of heart failure management in the elderly population
Cheng, J. W. M., & Nayar, M. (2009) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2009.10.001 · Cited by 73 · see citing works
Authors Task Force Members, Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M., Cosentino, F., Jönsson, B., Laakso, M., et al. (2007) · European Heart Journal Supplements · doi:10.1093/eurheartj/ehl261 · Cited by 73 · see citing works
Tribouilloy, C. M., Ruşinaru, D., Mahjoub, H., Tartiere, J.-H., Tartière-Kesri, L., Godard, S., & Peltier, M. (2008) · Heart · doi:10.1136/hrt.2007.128769 · Cited by 71 · see citing works
Cardiovascular disease and chronic kidney disease: Insights and an update
Best, P. J. M., Reddan, D. N., Berger, P. B., Szczech, L. A. M., McCullough, P. A., & Califf, R. M. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.04.011 · Cited by 70 · see citing works
Influence of diabetes on the survival of patients hospitalized with heart failure: a 12-year study
Varela-Roman, A., Shamagian, L. G., Caballero, E. B., Ramos, P. M., Veloso, P. R., & Gonzalez-Juanatey, J. R. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.01.017 · Cited by 69 · see citing works
SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
Li, N., & Zhou, H. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s269514 · Cited by 68 · see citing works
The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Ofstad, A. P., Atar, D., Gullestad, L. L., Langslet, G., & Johansen, O. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9685-0 · Cited by 59 · see citing works
VersorgungsLeitlinie, N. (2011) · Cited by 58 · see citing works
Extracellular Vesicles as Protagonists of Diabetic Cardiovascular Pathology
Gustafson, D., Veitch, S., & Fish, J. E. (2017) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2017.00071 · Cited by 54 · see citing works
The interplay of inflammation, exosomes and Ca2+ dynamics in diabetic cardiomyopathy
Sanganalmath, S. K., Dubey, S., Veeranki, S., Narisetty, K. K., & Krishnamurthy, P. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01755-1 · Cited by 53 · see citing works
Long-Term Outcome in Diabetic Heart Failure Patients Treated with Cardiac Resynchronization Therapy
Fantoni, C., Regoli, F. D., Ghanem, A., Raffa, S., Klersy, C., Sorgente, A., Faletra, F. F., Baravelli, M., Inglese, L. A., Salerno‐Uriarte, J. A., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.01.006 · Cited by 48 · see citing works
Haye, A., Ansari, M. A., Rahman, S. O., Shamsi, Y., Ahmed, D., & Sharma, M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173376 · Cited by 46 · see citing works
Hoppe, U. C., Freemantle, N., Cleland, J. G. F., Marijianowski, M., & Erdmann, E. (2007) · Diabetes Care · doi:10.2337/dc06-2035 · Cited by 43 · see citing works
Mega clinical trials which have shaped the RAS intervention clinical practice
Düsing, R. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716644131 · Cited by 43 · see citing works
Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control
Seferović, J. P., Solomon, S. D., & Seely, E. W. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820970444 · Cited by 40 · see citing works
Jiang, M., Huang, C., Wang, Q., Zhu, Y.-Y., Wang, J., Chen, J., & Shi, J. (2015) · Luminescence · doi:10.1002/bio.2984 · Cited by 39 · see citing works
Reyes, S., Varagić, J., Ahmad, S., VonCannon, J. L., Kon, N. D., Wang, H., Groban, L., Cheng, C. P., Dell’Italia, L. J., & Ferrario, C. M. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0708-3 · Cited by 39 · see citing works
Present Insights on Cardiomyopathy in Diabetic Patients
Felício, J. S., Koury, C. C., Carvalho, C. T., Neto, J. F. A., Miléo, K. B., Arbage, T. P., da Silva, D. D., de Oliveira, A. F., Peixoto, A. S., de Figueiredo, A. B., et al. (2015) · Current Diabetes Reviews · doi:10.2174/1573399812666150914120529 · Cited by 37 · see citing works
Update on Diabetic Cardiomyopathy: Inches Forward, Miles to Go
Tillquist, M. N., & Maddox, T. M. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0274-7 · Cited by 37 · see citing works
Molecular Mechanisms and Epigenetic Regulation in Diabetic Cardiomyopathy
Mittal, A., Garg, R., Bahl, A., & Khullar, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.725532 · Cited by 34 · see citing works
Prevalence and characteristics of diabetic patients in a chronic heart failure population
Kistorp, C., Galatius, S., Gustafsson, F., Faber, J., Corell, P., & Hildebrandt, P. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2004.10.024 · Cited by 33 · see citing works
Pharmacological interventions for heart failure in people with chronic kidney disease
Lunney, M., Ruospo, M., Natale, P., Quinn, R. R., Ronksley, P. E., Konstantinidis, I., Palmer, S. C., Tonelli, M. A., Strippoli, G. F., & Ravani, P. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466.pub2 · Cited by 33 · see citing works
Volpe, M., Tocci, G., & Pagannone, E. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121334 · Cited by 33 · see citing works
Unraveling and Targeting Myocardial Regeneration Deficit in Diabetes
Molinaro, C., Salerno, L., Marino, F., Scalise, M., Salerno, N., Pagano, L., Angelis, A. D., Cianflone, E., Torella, D., & Urbanek, K. (2022) · Antioxidants · doi:10.3390/antiox11020208 · Cited by 31 · see citing works
Rosolová, H., Čech, J., Šimon, J., Špinar, J., Jandová, R., sen, J. W., Holubec, L., & Topolčan, O. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.03.009 · Cited by 30 · see citing works
Ahmed, A., Aronow, W. S., & Fleg, J. L. (2006) · American Journal of Therapeutics · doi:10.1097/00045391-200607000-00009 · Cited by 29 · see citing works
(ESC), G. D. T. S. D. Y. E. C. D. L. S. E. D. C., & (EASD), D. L. S. E. P. E. E. D. L. D. (2007) · Revista Española de Cardiología · doi:10.1016/s0300-8932(07)75070-4 · Cited by 28 · see citing works
Recent advances in metabolic imaging
Gropler, R. J. (2013) · Journal of Nuclear Cardiology · doi:10.1007/s12350-013-9786-z · Cited by 27 · see citing works
Tappia, P. S. (2007) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y06-098 · Cited by 27 · see citing works
A Narrative Review of Diabetic Macroangiopathy: From Molecular Mechanism to Therapeutic Approaches
Yin, J., Fu, X., Luo, Y., Leng, Y., Ao, L., & Xie, C. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01532-7 · Cited by 25 · see citing works
Heart failure in the elderly: advances and challenges
Jugdutt, B. I. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.36 · Cited by 25 · see citing works
Go, Y. Y., Allen, J. C., Chia, S. Y., Sim, L. L., Jaufeerally, F. R., Yap, J. J. L., Ching, C. K., Sim, D., Kwok, B. W. K., & Liew, R. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.119 · Cited by 24 · see citing works
Ifuku, M., Takahashi, K., Hosono, Y., Iso, T., Ishikawa, A., Haruna, H., Takubo, N., Komiya, K., Kurita, M., Ikeda, F., et al. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13141 · Cited by 23 · see citing works
Phospholipid-Mediated Signaling and Heart Disease
Tappia, P. S., & Singal, T. (2008) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-1-4020-8831-5_11 · Cited by 23 · see citing works
The tissue renin-angiotensin-aldosterone system in diabetes mellitus
Hanes, D. S., Nahar, A., & Weir, M. R. (2004) · Current Hypertension Reports · doi:10.1007/s11906-004-0083-8 · Cited by 23 · see citing works
Marfella, R., D’Onofrio, N., Mansueto, G., Grimaldi, V., Trotta, M. C., Sardu, C., Sasso, F. C., Scisciola, L., Amarelli, C., Esposito, S., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01573-x · Cited by 21 · see citing works
Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy
Butler, J., Januzzi, J. L., & Rosenstock, J. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14042 · Cited by 19 · see citing works
Present and future pharmacotherapy for heart failure
Brown, L., & Doggrell, S. A. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.7.915 · Cited by 19 · see citing works
Hu, F., & Lin, C. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-04926-0 · Cited by 18 · see citing works
Fried, T. R., O’Leary, J. R., Towle, V. R., Goldstein, M. K., Trentelange, M., & Martin, D. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112593 · Cited by 18 · see citing works
Okoshi, K., Guimarães, J. F. C., Muzio, B. P. D., Fernandes, A. A. H., & Okoshi, M. P. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000200004 · Cited by 18 · see citing works
Diabetes and the heart: compromised myocardial function ? a common challenge
Bartnik, M. (2003) · European Heart Journal Supplements · doi:10.1016/s1520-765x(03)90039-3 · Cited by 18 · see citing works
CARDIOMYOPATHY AND HEART FAILURE IN DIABETES
Tang, W. H. W., & Young, J. B. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70226-7 · Cited by 18 · see citing works
Rydén, L., estable, G. D. T. D. L. S. E. D. C. S. D. Y. T. D. L. C. I., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H. P., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.10.015 · Cited by 17 · see citing works
DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety.
Paneni, F. (2015) · PubMed Central · doi:10.3978/j.issn.2223-3652.2015.09.06 · Cited by 17 · see citing works
Novel insight into the dangerous connection between diabetes and heart failure
Lombardi, C., Spigoni, V., Gorga, E., & Dei, A. (2016) · Herz · doi:10.1007/s00059-016-4415-7 · Cited by 17 · see citing works
Systolic heart failure in the elderly: optimizing medical management
Man, J. P., & Jugdutt, B. I. (2011) · Heart Failure Reviews · doi:10.1007/s10741-011-9282-y · Cited by 16 · see citing works
Pharmacological interventions for heart failure in people with chronic kidney disease
Ravani, P., Quinn, R. R., & Strippoli, G. F. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466 · Cited by 16 · see citing works
Fonseca, C., Brito, D. A., Branco, P. Q., Frazão, J. M., Silva‐Cardoso, J., & Bettencourt, P. (2020) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2020.03.015 · Cited by 16 · see citing works
High Dose Lisinopril in Heart Failure: Economic Considerations
Ess, S. M., Lüscher, T. F., & Szucs, T. D. (2002) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1021794229020 · Cited by 16 · see citing works
Schommer, N., Gendron, N., Krauel, K., Bruggen, S. V., Jarrot, P., Maier, A., Chan, W., Langer, H. F., Duerschmied, D., Westermann, D., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf963 · Cited by 15 · see citing works
Xiong, S., Sun, H., Cao, X., Wu, Z., Zhu, M., Cao, L., Nie, X.-W., & Bian, J. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0024 · Cited by 15 · see citing works
Yang, X., Zhao, X., Liu, Y., Liu, Y., Liu, L., An, Z., Xing, H., Tian, J., & Song, X. (2023) · Phytotherapy Research · doi:10.1002/ptr.7746 · Cited by 14 · see citing works
Dose response of ACE inhibitors: implications of the SECURE trial
Lonn, E. (2001) · Trials · doi:10.1186/cvm-2-4-155 · Cited by 14 · see citing works
Lee, K., Noh, J. H., Park, S., Choi, K. M., Kang, S., Won, K. C., Cho, H., Moon, M. K., & Korean Society of Heart Failure (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0420 · Cited by 13 · see citing works
Diabetic cardiomyopathy: factual or factoid?
Quinaglia, T., de Oliveira, D. C., Matos‐Souza, J. R., & Sposito, A. C. (2019) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.65.1.69 · Cited by 13 · see citing works
GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES
Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M. J., Cosentino, F., Jönsson, B., Laakso, M., Malmberg, K., et al. (2007) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2007-3-5-88-111 · Cited by 13 · see citing works
Conivaptan: promise of treatment in heart failure
Hoque, M. Z., Arumugham, P. S., Huda, N., Verma, N., Afiniwala, M., & Karia, D. H. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903173237 · Cited by 12 · see citing works
Morales, A., & Coca, A. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2009.02.038 · Cited by 11 · see citing works
Meindl, C., Hochadel, M., Frankenstein, L., Bruder, O., Pauschinger, M., Hambrecht, R., von Scheidt, W., Pfister, O., Hartmann, A., Maier, L. S., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234260 · Cited by 10 · see citing works
Gil-Ortega, I., & Kaski, J. C. (2006) · Medicina Clínica · doi:10.1157/13094003 · Cited by 9 · see citing works
- Authors
- RYDEN, L.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-12
- Volume
- 21
- Issue
- 23
- Pages
- 1967-1978
- ISSN
- 0195-668X (ISSN-L)
- OpenAlex
- W2109251059
- Cited by
- 174
- References
- 18
- Citations by year
- 2025: 2 · 2024: 5 · 2023: 8 · 2022: 8 · 2021: 4 · 2020: 15 · 2019: 11 · 2018: 3 · 2017: 10 · 2016: 6 · 2015: 9 · 2014: 13 · 2013: 6 · 2012: 5
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- lisinopril, chronic heart failure, diabetes mellitus, ATLAS trial, all-cause mortality, hospitalization, subgroup analysis, drug safety, renin-angiotensin system blockade, elderly patients, renal dysfunction, hyponatremia
- MeSH terms
- Aged, Aged, 80 and over, Angiotensin-Converting Enzyme Inhibitors, Chronic Disease, Drug Administration Schedule, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, New York, Retrospective Studies, Survival Analysis, Randomized Controlled Trials as Topic, Databases, Factual, Lisinopril, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
